Home Proteases -Epigenetics -Metabolism PAD

PAD

Isoform-selective Products

PAD Products

  • All (5)
  • PAD Inhibitors (5)
  • New PAD Products
Catalog No. Product Name Information Product Use Citations Product Validations
S8141 Cl-amidine Cl-amidine is an irreversible pan-peptidylarginine deiminase (PAD) inhibitor with IC50 values of 5.9 ± 0.3 μM, 0.8 ± 0.3 μM, 6.2 ± 1.0 μM for PAD4, PAD1 and PAD3, respectively. Cl-amidine induces apoptosis.
Immunity, 2025, S1074-7613(25)00069-X
Cell Rep, 2025, 44(2):115226
Nat Commun, 2024, 15(1):8663
S7803 GSK484 HCl GSK484 HCl, a benzoimidazole derivative, is a selective and reversible inhibitor of peptidylarginine deiminase 4 (PAD4) with IC50 of 50 nM in the absence of Calcium.
Cancer Cell, 2025, 43(1):69-85.e11
Biomolecules, 2025, 15(4)572
J Exp Clin Cancer Res, 2024, 43(1):319
S9644 BMS-P5 BMS-P5, a potent selective pharmacological inhibitor of PAD4, is used to evaluate the effect of PAD4 inhibition on multiple myeloma (MM)-induced neutrophil extracellular trap (NET) formation.
E4995New Cl-amidine hydrochloride Cl-amidine hydrochloride is an orally active peptidylarginine deminase (PAD) inhibitor, with IC50 values of 0.8 μM, 6.2 μM and 5.9 μM for PAD1, PAD3, and PAD4, respectively. Cl-amidine hydrochloride induces apoptosis in cancer cells. Cl-amidine hydrochloride induces microRNA (miR)-16 (miRNA-16, microRNA-16) expression and causes cell cycle arrest. Cl-Amidine hydrochloride prevents histone 3 citrullination and neutrophil extracellular trap formation, and improves survival in a murine sepsis model[1][2][3][4][5].
S7802New GSK199 GSK199 is a reversible, specific inhibitor of peptidyl arginine deiminase 4 (PAD4), with an IC50 of 200 nM without calcium. It is involved in histone citrullination and neutrophil extracellular trap formation, making it useful for studying autoimmune, cardiovascular, and oncological diseases.
S8141 Cl-amidine Cl-amidine is an irreversible pan-peptidylarginine deiminase (PAD) inhibitor with IC50 values of 5.9 ± 0.3 μM, 0.8 ± 0.3 μM, 6.2 ± 1.0 μM for PAD4, PAD1 and PAD3, respectively. Cl-amidine induces apoptosis.
Immunity, 2025, S1074-7613(25)00069-X
Cell Rep, 2025, 44(2):115226
Nat Commun, 2024, 15(1):8663
S7803 GSK484 HCl GSK484 HCl, a benzoimidazole derivative, is a selective and reversible inhibitor of peptidylarginine deiminase 4 (PAD4) with IC50 of 50 nM in the absence of Calcium.
Cancer Cell, 2025, 43(1):69-85.e11
Biomolecules, 2025, 15(4)572
J Exp Clin Cancer Res, 2024, 43(1):319
S9644 BMS-P5 BMS-P5, a potent selective pharmacological inhibitor of PAD4, is used to evaluate the effect of PAD4 inhibition on multiple myeloma (MM)-induced neutrophil extracellular trap (NET) formation.
E4995New Cl-amidine hydrochloride Cl-amidine hydrochloride is an orally active peptidylarginine deminase (PAD) inhibitor, with IC50 values of 0.8 μM, 6.2 μM and 5.9 μM for PAD1, PAD3, and PAD4, respectively. Cl-amidine hydrochloride induces apoptosis in cancer cells. Cl-amidine hydrochloride induces microRNA (miR)-16 (miRNA-16, microRNA-16) expression and causes cell cycle arrest. Cl-Amidine hydrochloride prevents histone 3 citrullination and neutrophil extracellular trap formation, and improves survival in a murine sepsis model[1][2][3][4][5].
S7802New GSK199 GSK199 is a reversible, specific inhibitor of peptidyl arginine deiminase 4 (PAD4), with an IC50 of 200 nM without calcium. It is involved in histone citrullination and neutrophil extracellular trap formation, making it useful for studying autoimmune, cardiovascular, and oncological diseases.
E4995New Cl-amidine hydrochloride Cl-amidine hydrochloride is an orally active peptidylarginine deminase (PAD) inhibitor, with IC50 values of 0.8 μM, 6.2 μM and 5.9 μM for PAD1, PAD3, and PAD4, respectively. Cl-amidine hydrochloride induces apoptosis in cancer cells. Cl-amidine hydrochloride induces microRNA (miR)-16 (miRNA-16, microRNA-16) expression and causes cell cycle arrest. Cl-Amidine hydrochloride prevents histone 3 citrullination and neutrophil extracellular trap formation, and improves survival in a murine sepsis model[1][2][3][4][5].
S7802New GSK199 GSK199 is a reversible, specific inhibitor of peptidyl arginine deiminase 4 (PAD4), with an IC50 of 200 nM without calcium. It is involved in histone citrullination and neutrophil extracellular trap formation, making it useful for studying autoimmune, cardiovascular, and oncological diseases.

Choose Selective PAD Inhibitors

Tags: PAD inhibitor|PAD agonist|PAD activator|PAD inducer|PAD antagonist|PAD signaling pathway|PAD assay kit